POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.

被引：0
|
作者：
Lee, J. I. [1 ]
Jung, S. Y. [1 ]
Yug, J. S. [2 ]
Chung, E. K. [2 ]
Keedy, V. L. [3 ]
Bauer, T. M. [4 ,5 ]
Clarke, J. M. [6 ]
Hurwitz, H. [6 ]
Lee, H. [7 ]
Park, N. [7 ]
Lee, S. [7 ]
Kim, H. -K. [7 ]
Baek, I. [8 ]
Hwang, S. [8 ]
Nam, S. Y. [8 ]
Ha, I. [8 ]
Kim, S. -J. [8 ]
机构：
[1] Seoul Natl Univ, Seoul, South Korea
[2] Kyung Hee Univ, Seoul, South Korea
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Tennessee Oncol, Nashville, TN USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Natl Canc Ctr, Natl OncoVenture, Goyang, South Korea
[8] MedPacto Inc, Suwon, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-074
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [21] A Phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Hurwitz, HI
    Eckhardt, SG
    Holden, SN
    Basser, R
    Deboer, R
    Rosenthal, M
    Rischin, D
    Swaisland, H
    Barge, A
    McKinley, M
    Wheeler, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3654S - 3654S
  • [22] Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors.
    Bonate, P
    Ebbinghaus, S
    Eder, JP
    Mita, A
    Rubin, E
    Cunningham, CC
    Rowinsky, EK
    Hersh, E
    Craig, AR
    Hammond, LA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 147S - 147S
  • [23] A phase II double window of opportunity trial evaluating the oral TGF-beta receptor I inhibitor vactosertib in patients undergoing standard of care preoperative therapy for locally advanced esophageal adenocarcinoma.
    Patell, Kanchi
    Henke, Lauren E.
    Dorth, Jennifer Anne
    Lumish, Melissa Amy
    Conces, Madison
    Mohamed, Amr
    Chakrabarti, Sakti
    Mahipal, Amit
    Bajor, David L.
    Blum, Andrew
    Guda, Kishore
    Selfridge, J. Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS516 - TPS516
  • [24] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Xu, Jian Ming
    Wang, Yan
    Chen, Yu Ling
    Jia, Ru
    Li, Jie
    Gong, Ji Fang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    Tan, Cui Rong
    Wang, Jian
    Li, Ke
    Sai, Yang
    Zhou, Feng
    Ren, Yong Xin
    Qing, Wei Guo
    Jia, Hong
    Su, Wei Guo
    Shen, Lin
    ONCOTARGET, 2017, 8 (26) : 42076 - 42086
  • [25] A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
    Schwartz, Gary K.
    Adkins, Douglas
    Heist, Rebecca Suk
    Abbott, Maura
    Barber, Stephanie L.
    Chao, Richard C.
    Neuteboom, Saskia T. C.
    Chen, Isan
    Christensen, James
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors
    Zhou, Xiaofei
    Ouerdani, Aziz
    Diderichsen, Paul Matthias
    Gupta, Neeraj
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (03): : 422 - 433
  • [27] Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors
    Zhou, Qing
    Wu, Yi Long
    Yu, Xiyong
    Yang, Jinji
    Wen, Limin
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Phase I and pharimacokinetic trial of a novel inhibitor of NAD biosynthesis in patients with solid tumors.
    Holen, KD
    Bolling, C
    Saltz, LB
    Graefe, T
    Ty, V
    Sogo, N
    Starkmann, H
    Burk, KH
    Hollywood, E
    Hanauske, AR
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6158S - 6158S
  • [29] Phase I and pharmacokinetics/pharmacodynamics (PK/PD) study of MEK inhibitor, RO4987655, in Japanese patients with advanced solid tumors.
    Yamada, Yasuhide
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Fujiwara, Yutaka
    Tamura, Yosuke
    Wakui, Hiroshi
    Honda, Kazunori
    Nakamichi, Shinji
    Asahina, Hajime
    Tanabe, Yuko
    Kitazono, Satoru
    Mizugaki, Hidenori
    Yamazaki, Naoya
    Suzuki, Shigenobu
    Sasaki, Junichi
    Matsuoka, Mieko
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [30] AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.
    Yap, Timothy A.
    Lakhani, Nehal J.
    Araujo, Daniel Vilarim
    Ahnert, Jordi Rodon
    Chandana, Sreenivasa R.
    Sharma, Manish
    Denis, Jean-Francois
    Gruosso, Tina
    Tremblay, Gilles
    O'Connor, Maureen
    Ghosh, Ria
    Sinclair, Sandra
    Wood, Debra L.
    Nadler, Paul, I
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345